ClinicalTrials.gg
Drug

Apremilast clinical trials

Also written Otezla, CC-10004 and AMG 407.

studies test it
117
open now
15
in phase 3
28
first study started
2005

How each study uses apremilast is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the apremilast studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 Mar 2014 · OTEZLA · NDA 205437 (FDA, Drugs@FDA)
European Union
15 Jan 2015 · Otezla · EMEA/H/C/003746 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Apremilast
86
Apremilast 30mg
12
Apremilast 20mg
5
Apremilast (CC-10004)
4
Apremilast 30 mg
3

Brand

Otezla
52

Development codes

CC-10004
35
AMG 407
5

Studies by the year they started

117 studies that test it; most in 2010 (15)

Studies that test apremilast, by start year
YearStudies
20051
20061
20072
20085
20095
201015
20125
20132
20143
20155
20168
201711
201812
201912
20206
20212
20226
20235
20243
20251
20267

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
12
Phase 2
48
Phase 3
28
Phase 4
28
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 48 · Other 69

Amgen (46) · Icahn School of Medicine at Mount Sinai (3) · Yale University (2) · Tufts Medical Center (2) · Psoriasis Treatment Center of Central New Jersey (2) · University Hospitals Cleveland Medical Center (2) · Oregon Health and Science University (2) · Derm Research, PLLC (2)

Often tested with

Tested in the same studies.

Etanercept (4) · Methotrexate (4) · Cyclosporine (3) · Adalimumab (3) · Secukinumab (3) · Ustekinumab (3) · Remdesivir (2) · Imatinib (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Apremilast is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test apremilast, phase 3 first.

Studies

Open first, then newest update. How each study uses apremilast is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 117

See all 117 studies that test apremilast →

Given beside what is tested · 5 — apremilast is usual care or a partner of the new treatment
As the comparator · 10 — what is tested is compared with apremilast

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call apremilast · ClinicalTrials.gg INT004838

  • MeSH (NLM) C505730apremilastConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) UP7QBP99PNAPREMILASTConfirmed FDA, NLM, Wikidata
  • RxNorm 1492727Confirmed FDA, Wikidata
  • Wikidata Q2858961apremilastConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C147044ApremilastOne source FDA
  • DrugBank DB05676One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.